Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
- PMID: 15871997
- PMCID: PMC1774768
- DOI: 10.1136/gut.2005.065136
Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications
Abstract
Background: Identifying risk factors for the development of complications of chronic hepatitis B (CHB) is important for setting up treatment criteria.
Aim: To determine risk factors for the development of complications in Asian CHB patients.
Patients and methods: A total of 3233 Chinese CHB patients (mean follow up 46.8 months) were monitored for liver biochemistry, viral serology, hepatitis B virus (HBV) DNA levels, acute exacerbation, hepatitis B e antigen (HBeAg) seroconversion, and development of cirrhotic complications and hepatocellular carcinoma.
Results: Median age for HBeAg seroconversion and development of complications was 35 years and 57.2 years, respectively. Patients with alanine aminotransferase (ALT) levels of 0.5-1 times the upper limit of normal (ULN) and 1-2x ULN had an increased risk for the development of complications compared with patients with ALT levels <0.5x ULN (p<0.0001 for both). HBeAg/antibody to hepatitis B e antigen status, and number of episodes, duration, and peak ALT levels of acute exacerbations were not associated with an increased risk of complications. In patients with complications, 43.6% had HBV DNA levels less than 1.42x10(5) copies/ml. Male sex, stigmata of chronic liver disease, old age, low albumin, and high alpha fetoprotein levels on presentation were independently associated with increased cumulative risk of complications. Male sex, presence of hepatitis symptoms, old age, low albumin level, and presence of complications on presentation were independently associated with shorter survival.
Conclusion: Prolonged low level viraemia causing insidious and continual liver damage, as reflected by ALT levels of 0.5-2x ULN, is the most likely pathway for the development of complications in Asian CHB patients.
Figures
Comment in
-
Predicting survival in hepatitis B.Gut. 2005 Nov;54(11):1521-3. doi: 10.1136/gut.2005.071332. Gut. 2005. PMID: 16227355 Free PMC article. Review. No abstract available.
-
Do baseline ALT levels predict complications of chronic hepatitis B?Gut. 2006 May;55(5):745; author reply 745-6. Gut. 2006. PMID: 16609140 Free PMC article. No abstract available.
Similar articles
-
A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy.Gut. 2003 Mar;52(3):416-9. doi: 10.1136/gut.52.3.416. Gut. 2003. PMID: 12584226 Free PMC article.
-
Treatment of chronic hepatitis B: case selection and duration of therapy.J Gastroenterol Hepatol. 2002 Apr;17(4):409-14. doi: 10.1046/j.1440-1746.2002.02767.x. J Gastroenterol Hepatol. 2002. PMID: 11982721 Review.
-
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients.Aliment Pharmacol Ther. 2020 Jun;51(11):1169-1179. doi: 10.1111/apt.15725. Epub 2020 Apr 14. Aliment Pharmacol Ther. 2020. PMID: 32291781
-
Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.Clin Gastroenterol Hepatol. 2013 Nov;11(11):1493-1499.e2. doi: 10.1016/j.cgh.2013.05.038. Epub 2013 Jun 28. Clin Gastroenterol Hepatol. 2013. PMID: 23811251
-
Systematic review with meta-analysis: the proportion of chronic hepatitis B patients with normal alanine transaminase ≤ 40 IU/L and significant hepatic fibrosis.Aliment Pharmacol Ther. 2014 Feb;39(4):349-58. doi: 10.1111/apt.12590. Epub 2014 Jan 6. Aliment Pharmacol Ther. 2014. PMID: 24387289 Review.
Cited by
-
Efficacy of tenofovir disoproxil fumarate therapy in nucleoside-analogue naive Iranian patients treated for chronic hepatitis B.Hepat Mon. 2015 May 23;15(5):e25749. doi: 10.5812/hepatmon.15(5)2015.25749. eCollection 2015 May. Hepat Mon. 2015. PMID: 26045705 Free PMC article.
-
High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.PLoS One. 2012;7(8):e43087. doi: 10.1371/journal.pone.0043087. Epub 2012 Aug 20. PLoS One. 2012. PMID: 22916211 Free PMC article.
-
The Role of Antiviral Therapy for HBV-Related Hepatocellular Carcinoma.Int J Hepatol. 2011;2011:416459. doi: 10.4061/2011/416459. Epub 2011 May 30. Int J Hepatol. 2011. PMID: 21994855 Free PMC article.
-
Viral hepatitis B: clinical and epidemiological characteristics.Cold Spring Harb Perspect Med. 2014 Oct 30;4(12):a024935. doi: 10.1101/cshperspect.a024935. Cold Spring Harb Perspect Med. 2014. PMID: 25359547 Free PMC article. Review.
-
Natural history of chronic hepatitis B: phases in a complex relationship.World J Gastroenterol. 2014 Aug 14;20(30):10395-404. doi: 10.3748/wjg.v20.i30.10395. World J Gastroenterol. 2014. PMID: 25132755 Free PMC article. Review.
References
-
- Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733–45. - PubMed
-
- Lai CL. Chronic hepatitis B in Hong Kong: immunization strategies for the control of hepatitis B virus infection. In: Zuckerman, ed. Hepatitis B in the Asian-Pacific region vol. 1 screening, diagnosis and control. London: Royal College of Physicians, 1997:79–87.
-
- Beasley RP, Hwang LY. Overview on the epidemiology of hepatocellular carcinoma. In: Hollinger FB, Lemon SM, Margolis H, eds. Viral hepatitis and liver diseases. Baltimore: Williams and Wilkins, 1991:532–5.
-
- Maddrey WC. Hepatitis B—an important public health issue. Clin Lab 2001;47:51–5. - PubMed
-
- Lok ASF, McMahon BJ. Chronic hepatitis B. Hepatology 2001;34:1225–41. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources